Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2026)

Arcturus Therapeutics Holdings has reported Free Cash Flow for 9 years, with the latest figure at -$19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 44.89% year-over-year to -$19.4 million; the trailing twelve-month figure through Mar 2026 stood at -$58.7 million (up 34.72% YoY), and the FY2025 full-year result was -$74.5 million, down 23.36% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$19.4 million, down from -$16.4 million in the prior quarter.
• The five-year high for Free Cash Flow was $156.5 million in Q4 2022, with the low at -$51.2 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$8.9 million across 5 years, with a median of -$19.4 million in 2026.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 488.58% — and 2025, when it tumbled 5664.08%.
• Arcturus Therapeutics Holdings' Free Cash Flow stood at $156.5 million in 2022, then plunged by 100.96% to -$1.5 million in 2023, then surged by 81.12% to -$284000.0 in 2024, then plunged by 5664.08% to -$16.4 million in 2025, then declined by 18.76% to -$19.4 million in 2026.
• The last three Free Cash Flow figures came in at -$19.4 million (Q1 2026), -$16.4 million (Q4 2025), and -$17.1 million (Q3 2025), per Business Quant data.